Reporter | Line 1^ | Line 2^ | Line 3^ | Line 4^ |
|---|
pvit-2(2.0):gfp
| 68%(0, 1) | 37%(0.1, 5) | 30%(0.2, 5) | 35%(0, 1) |
pvit-2(1.5):gfp
| 47%(0.04, 2) | Â | Â | Â |
pvit-2(0.8):gfp
| 26% (0.2, 5)* | 48%(0.2, 2) | Â | Â |
pvit-2(0.3):gfp
| 30%(0, 1) | 40%(0, 1) | 24%(0, 1) | Â |
pgly-19:gfp
| -3% (0, 1) | -28%(0, 1) | Â | Â |
- ^ Relative GFP fluorescence (SD, trials). Data show % change (SD, trials) of average maximum GFP fluorescence from daf-16 RNAi versus control in daf-2(e1370) hermaphrodites. Positive values indicate increased pvit-2:GFP fluorescence associated with reduced daf-16 activity from RNAi. Bold indicates GFP intensity was significantly different in daf-16 RNAi-treated animals in all trials (p < 0.05, T-test).
- * GFP fluorescence intensity increased statistically significantly in 3/5 trials (p ≤ 0.05, T-test). In the remaining 2 trials, % GFP intensity change on daf-16 RNA was +5% (p = 0.3) and +6% (p = 0.6)
